Individuals with Down syndrome (DS) have specific health care needs and require additional screening and surveillance for commonly associated conditions. The American Academy of Pediatrics (AAP) Committee on Genetics has […]
I reviewed a question on the Down Syndrome Medical Interest Group Listserv about a 31-year-old person with Down syndrome who was slowing down. It was reported that it could take […]
There can be many reasons that might cause challenging behaviors in people with Down syndrome (DS), including the inability to communicate the presence of a problem being faced, underlying physical […]
LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch of the DS-CTN Data and Safety Monitoring Board (DSMB). This service was created to provide […]
Individuals with Down syndrome have fewer viral infections, but when infected, they suffer from more severe disease. Malle et al. find that triplication of IFNAR1 and IFNAR2, the receptor subunits […]
Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced positive “topline” results from the clinical trial of their anti-amyloid antibody, lecanemab, in patients with […]
